The European Commission signed its second contract to purchase future potential COVID-19 vaccines, this time with Sanofi-GSK following its contract with AstraZeneca.
Should the vaccine prove effective, the deal includes 300 million doses of Sanofi-GSK’s vaccine candidate, which could be available by the second half of 2021. It also includes the potential to donate doses to lower- and middle-income countries or to redirect to other European countries. Sanofi-GSK’s vaccine candidate is currently in large-scale Phase II/III clinical trials.
Press release - European Commission